ination; 2) presence of an aneurysm angiographically confirmed to be the source of the hemorrhage; and 3) presentation to the hospital within 7 days postictus. Patients were excluded for the presence of arteriovenous malformation, other vascular anomaly, or trauma confounding the identification of the source of the hemorrhage. Intraparenchymal hemorrhage, when present, was not a criterion for exclusion if the majority of the hemorrhage was subarachnoid. Demographic and pertinent clinical data were extracted from patient records.
Aspirin use was identified by the patient's medical history and physical examination obtained at admission, by a health questionnaire completed by the patient or a family member at admission, or by the most recent clinical notes made before onset of the SAH, which indicated regular aspirin use without evidence of a change in this regimen. Any duration of aspirin use before the ictus was included and aspirin use to relieve a headache associated with a likely sentinel hemorrhage was included if it was clearly separate from the ictal event leading to hospital admission. Rebleeding was defined as a clinical deterioration with evidence of recurrent hemorrhage on the CT scan. Symptomatic vasospasm was defined as a focal or global neurological deficit referable to one or more vascular territories, in which transcranial Doppler measurements or cerebral angiography indicated arterial narrowing believed to have caused the neurological findings. Deficits from symptomatic vasospasm could not be explained by other causes of neurological deterioration (rebleeding, acute or worsening hydrocephalus, electrolyte disturbances, hypoxia, or seizures). The determination of a permanent deficit from vasospasm and global GOS 9 scores were assigned to data collected at the longest available follow-up point (mean 16.4 months, range 3 days-10 years).
Statistical Analysis
Comparisons between aspirin use and categorical variables were made using chi-square tests or Fisher exact tests when sample sizes were limited. Comparisons of mean values for continuous variables between aspirin users and nonusers were made using a two-sample t-test or the Wilcoxon rank-sum test.
Adjusted logistic regression models for the odds of preoperative rebleeding and the odds of permanent deficit due to vasospasm were constructed to incorporate potential confounders into the analysis. Models included aspirin use, patient age, Hunt and Hess 7 grade at admission, and a location of the aneurysm in the posterior circulation. Similar models were also used for the odds of clinical vasospasm, odds of permanent deficit due to vasospasm, and odds of poor outcome (GOS Score Յ 3) at the longest available follow up.
Results
A review of 1319 medical records was made. Three hundred eight medical records met the study inclusion criteria. The records of three patients were excluded from the study because research authorization was denied, leaving 305 patient records for analysis. Of the 305 patients, 29 (9.5%) had a history of aspirin use before they experienced an SAH. Eighteen of these 29 patients used aspirin daily or every other day, whereas the remaining 11 patients used aspirin as needed for analgesia. The daily dose of aspirin ranged from 81 to 1950 mg. Aspirin users were older on average than nonusers (59 years of age compared with 53 years; p = 0.018). The mean admission Hunt and Hess grades of patients who used or did not use aspirin were similar (2 compared with 2.3; p = 0.51). Aspirin users were not statistically different from nonusers with regard to sex, history of hypertension, need for ventricular drainage or a shunt, or rate of surgical repair compared with endovascular treatment (Table 1) . Aspirin users were slightly less likely to harbor posterior circulation aneurysms, but this difference was not significant (13.8% compared with 30.8%; p = 0.06). There was no statistical difference in treatment parameters between the two groups ( Table 2) .
The outcome data illustrated two trends, neither of which reached statistical significance (Table 3) . First, there was an increased rate of rebleeding in aspirin users (14.3% compared with a 4.7% rebleeding rate in nonusers; p = 0.06). Second, the overall incidence of symptomatic vasospasm did not differ between aspirin users and nonusers (46% compared with 37%; p = 0.44); however, there was a tendency for nonusers to die or suffer a permanent disability from vasospasm at a higher rate than aspirin users (50% compared with 23%; p = 0.069). In the entire series, preoperative rebleeding was associated with an increased risk of a poor outcome (GOS Score Յ 3) at the last follow-up point (62.5% of patients with repeated bleeding had GOS Score Յ 3 compared with 31.3% of those with no repeated bleeding; p = 0.01). Overall outcomes did not differ between aspirin users and nonusers (mean GOS Scores 3.83 and 3.86, respectively; p = 0.82). An examination of the GOS score as a categorical variable (Grade Յ 3 compared with Ն 4) also showed that aspirin use was not associated with a worse outcome (34.5% of aspirin users and 33% of nonusers with a poor outcome; p = 0.87). Controlling for patient age, Hunt and Hess grade, and location of the aneurysm in the posterior circulation did not alter the findings substantially (Table 4) .
Discussion
Aspirin is a potent inhibitor of platelet activation. Its effects are mediated largely through irreversible acetylation of specific serine residues on prostaglandin H synthase-1 and -2, which are also known as cyclooxygenase-1 and -2, respectively. These enzymes catalyze the first two steps in the metabolic pathway from arachidonic acid to prostaglandin synthesis. The best-characterized metabolic products of this pathway include prostacyclin and thromboxane A 2 , which mediate contradictory effects on platelet activation and vascular smooth-muscle tone. Anucleate platelets cannot regenerate the cyclooxygenase enzyme, thereby allowing aspirin to induce an unrecovered depletion of thromboxane. The synthesis of prostacyclin in vascular endothelial cells remains because these cells can actively regenerate the cyclooxygenase enzyme to overcome aspirin inhibition. The net effect of aspirin is an inhibition in platelet activation and, thereby, a reduction in platelet-mediated thrombus formation.
In the setting of SAH, previous aspirin use carries the theoretical risks of exacerbating the initial hemorrhage, increasing the rate of rebleeding, and complicating surgical procedures intended to secure the source of bleeding. Some evidence indicates that inhibitors of clot formation can complicate SAH. Systemic anticoagulation with warfarin therapy has been associated with poor outcome after SAH, 22 whereas nonsteroidal antiinflammatory drug therapy after SAH has been implicated as a risk factor for intra-and postoperative hemorrhage. 16 These risks, however, have not been translated to aspirin use, based on the results of a pilot trial of aspirin therapy following aneurysm clipping after SAH. 6 In contrast, there are theoretical benefits to aspirin therapy in patients with SAH. The efficacy of aspirin in decreasing vascular smooth-muscle tone has been the impetus for undertaking animal and human investigations of aspirin in the treatment of post-SAH cerebral vasospasm. Animal models of SAH have shown a direct correlation among platelet activation, prostaglandin synthesis, and cerebral vasospasm. 4, 19, 25 These models have also demonstrated the efficacy of aspirin therapy in attenuating cerebral vasospasm following SAH. 15, 24, 27 Data are available in humans that again correlate thromboxane synthesis and platelet activation with a delayed ischemic neurological deficit from vasospasm. 14, 17 At least one author has reported reduced com-
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Influence of aspirin on outcome after aneurysmal SAH plications from vasospasm in patients taking aspirin before they suffered an SAH. 11 Analysis of our data indicates that the overall clinical outcome following aneurysmal SAH in patients taking aspirin before hemorrhage is not different from those who were not taking aspirin. It must be emphasized, however, that trends not reaching statistical significance were identified, indicating that patients taking aspirin before SAH were more likely to suffer from rebleeding episodes, but less likely to suffer permanent deficit from vasospasm. Therefore, there is no net effect of aspirin use on outcome-the result of balancing an increasing risk of repeated hemorrhage and a decreasing risk of vasospasm-induced permanent deficits.
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The trend toward an increased risk of rebleeding in aspirin users is presumably based on impaired or unstable thrombus formation at the site of rupture on the aneurysm dome. An additional contributing mechanism may also be related to an immediate reduction in local vasospasm due to the direct vasodilatory effects of aspirin, which preserve a high arterial pressure to the rupture site. Rebleeding usually worsens clinical outcomes 18 and did so in our entire series. It is possible that aspirin use predisposes patients with SAH to rebleeding episodes that are different from those experienced by nonusers-more frequent but smaller and/or less damaging. We are not ready, however, to base clinical recommendations on this conjecture. The most likely explanation for the lack of a difference in clinical outcome between the two groups is that the increased morbidity associated with increased repeated hemorrhage is counterbalanced by reduced vasospasm-related deficits in aspirin users. A systematic bias of the study toward better outcomes in aspirin users cannot be entirely excluded, because identification of aspirin use could have been less reliable in patients with clinically poor grades. Inclusion of familyprovided and previously documented medical information should have minimized this effect. Additionally, data on patients suffering sudden or early death from SAH who failed to be referred to our institution are not available for inclusion in this study.
The observed trend of reduced death or permanent deficit from symptomatic vasospasm in aspirin users is consistent with the findings of previous studies. Substantive scientific evidence supports the theory that the effects of aspirin on the arachidonic acid metabolic pathway and platelet activation could protect patients from vasospasm. 4, 15, 17, 26 Such observations have been the impetus for performing a clinical trial of aspirin following SAH. 6 Our data do not apply to therapeutic aspirin administration after SAH, and some reports indicate that a beneficial effect only occurs in those patients who take aspirin before SAH. 8 Additional data on the safety and therapeutic benefit of aspirin use after SAH should clarify this issue.
Assessing the advisability of aspirin use in patients with known unruptured aneurysms requires more data. Prospective trials have not confirmed an aspirin-induced increase in aneurysmal SAH. 1, 3 This study does not directly address the risk of rupture in patients with unruptured aneurysms who are on an aspirin regimen or the risk of ictal death from SAH. Although we acknowledge the trends shown in our data, based on the equivalent outcomes in patients in both groups we can offer no compelling recommendation against aspirin use in patients harboring unruptured intracranial aneurysms.
Conclusions
The findings of this study indicate trends toward an increased risk of rebleeding and a decreased risk of a permanent neurological deficit from vasospasm in patients who used aspirin before they suffered an SAH. The overall clinical outcomes in aspirin users, however, balance these risks and were no different from those of patients who had not used aspirin. The therapeutic benefit of aspirin use for vasospasm following SAH, particularly once an aneurysm has been secured by clipping or coil embolization, awaits further delineation.
